New investment for CatSci
Drug development firm CatSci has secured £4.5 million of investment from ‘alternative lender’ Boost & Co. This is described as a continuation of the Cardiff-based firm’s £3 million investment, which was started in 2021.
CatSci will use the funding to install new equipment and expand its laboratories by adding capabilities in chemical and analytical development, material science, product formulation and GMP analytical testing in both Cardiff and London. Some will be used to refinance its existing debt.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
